FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
FDA fast-tracks AbbVie’s spinal injury drugThe FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be Share XFDA fast-tracks AbbVie’s spinal injury drughttps://pharmaphorum.com/news/fda-fast-tracks-abbvies-spinal-injury-drug/
Despite biosims, ulcerative colitis drugs still cost too much; ICERNone of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough Share XDespite biosims, ulcerative colitis drugs still cost too much; ICERhttps://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/
AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drugAbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record Share XAbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drughttps://pharmaphorum.com/news/abbvie-signs-2-9bn-deal-with-i-mab-for-dont-eat-me-cancer-drug/
Gilead eyes takeover of cancer biotech Tizona, despite its ties to AbbVieGilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – Share XGilead eyes takeover of cancer biotech Tizona, despite its ties to AbbViehttps://pharmaphorum.com/news/gilead-eyes-takeover-of-cancer-biotech-tizona-despite-its-ties-to-abbvie/
J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayThe FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 Share XJ&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayhttps://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
Saunders steps aside as AbbVie closes in on Allergan mergerThe US competition regulator has finally approved the $63 billion takeover of Allergan by AbbVie, but only by Share XSaunders steps aside as AbbVie closes in on Allergan mergerhttps://pharmaphorum.com/news/saunders-steps-aside-as-abbvie-closes-in-on-allergan-merger/
